Literature DB >> 7490444

Antimicrobial prophylaxis of infection.

G M Dickinson1, A L Bisno.   

Abstract

Antimicrobial agents are used to prevent infections in a variety of clinical circumstances. In certain instances, the precise indications for prophylaxis remain controversial, and the preferred regimens undergo alterations based upon evolving clinical experience, changing patterns of microbial susceptibility, and innovations in medical and surgical practice. This article outlines the general principles underlying the use of antimicrobial prophylaxis and presents recommendations for the use of such prophylaxis in three areas: (1) surgery involving contaminated, clean-contaminated, and clean procedures; (2) prevention of infections due to specific pathogens, including Neisseria meningitidis, Hemophilus influenzae, Streptococcus pneumoniae, and Streptococcus pyogenes; and (3) prevention of infective endocarditis.

Entities:  

Mesh:

Year:  1995        PMID: 7490444

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  4 in total

1.  The identification of barriers preventing the successful implementation of a surgical prophylaxis protocol.

Authors:  Kathryn M Burnett; Michael G Scott; Patricia M Kearney; W George Humphreys; Robert M McMillen
Journal:  Pharm World Sci       Date:  2002-10

2.  Implementation and evaluation of a preprinted perioperative antimicrobial prophylaxis order form in a teaching hospital.

Authors:  P Au; S Salama; C Rotstein
Journal:  Can J Infect Dis       Date:  1998-05

Review 3.  Methicillin-resistant staphylococci in clean surgery. Is there a role for prophylaxis?

Authors:  E Mini; S Nobili; P Periti
Journal:  Drugs       Date:  1997       Impact factor: 9.546

4.  Vascular graft infection by Staphylococcus aureus: efficacy of linezolid, teicoplanin and vancomycin systemic prophylaxis protocols in a rat model.

Authors:  E Atahan; N Katrancioglu; Y Oztop; E Tuncer; H Ozer; S Manduz; E Engin; T D Yalta; O Berkan; K Dogan
Journal:  Cardiovasc J Afr       Date:  2009 Mar-Apr       Impact factor: 1.167

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.